Back to search

Article

Extended interval BNT162b2 vaccination enhances peak antibody generation in older people

2021-05-17

Abstract excerpt

<h4>Objectives</h4> To assess the relative immunogenicity of standard or extended interval BNT162b2 vaccination. <h4>Design</h4> Population based cohort study comparing immune responses 2 weeks after the second vaccine, with appropriate time-matched samples in participants who received standard or extended interval double vaccination. <h4>Setting</h4> Primary care networks, Birmingham, UK. December 2020 to April 2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eb2133bd-4338-538d-a241-1ebbf3b3563b
DOI
10.1101/2021.05.15.21257017
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Extended interval BNT162b2 vaccination enhances peak antibody generation in older peopleDOI 10.1101/2021.05.15.21257017
Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1Semantic proximity
Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialSemantic proximity
Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity
Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA VaccineSemantic proximity
Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity
Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccineSemantic proximity
Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationSemantic proximity
Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2Semantic proximity
SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationSemantic proximity
Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunitySemantic proximity
BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity
Select a neighboring publication to make it the new centre.